Nurse Practitioner Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Carol Matthews

Registered Nurse, General Practice Springfield, MO Nurse Practitioner

NPI 1619949427 CMS profile 11143691

909 E Republic Rd Ste D200, Springfield, MO 65807

Open in the dashboard

General payments

$5,182

145 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Carol Matthews of Springfield, MO is reported in the CMS Open Payments database as having received $5,182 across 145 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Registered Nurse, General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $31 1
2022 General $964 49
2021 General $4,188 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carol Matthews
  • Registered Nurse, General Practice median
  • Middle half of Registered Nurse, General Practice
  • National median

In program year 2025, general payments to Carol Matthews were reported at $0. Among 146 Registered Nurse, General Practice profiles paid that year, the median was $117 and the middle half received between $27 and $348.

Show as a table
Year Carol Matthews Registered Nurse, General Practice median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $4,188 $92 $30–$313 $132
2022 $964 $85 $28–$243 $149
2023 $31 $121 $51–$290 $160
2024 $0 $127 $42–$316 $164
2025 $0 $117 $27–$348 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. AbbVie, Inc. $1,838 42 payments
  2. Allergan Inc. $1,257 2 payments
  3. Biohaven Pharmaceuticals, Inc. $644 34 payments
  4. Lilly USA, LLC $472 23 payments
  5. Amgen Inc. $317 18 payments
  6. Teva Pharmaceuticals USA, Inc. $143 5 payments
  7. AstraZeneca Pharmaceuticals LP $142 3 payments
  8. Lundbeck LLC $127 5 payments
  9. Janssen Biotech, Inc. $66 4 payments
  10. Amneal Pharmaceuticals LLC $55 2 payments
  11. Other $121 7 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $2,663 141 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,500 2 payments
  3. Education $19 2 payments
Products named General payments · program years 2021–2023
  1. UBRELVY $2,789 20 payments
  2. NURTEC ODT $644 34 payments
  3. EMGALITY $281 8 payments
  4. REYVOW $267 7 payments
  5. Enbrel $216 13 payments
  6. TALTZ $191 15 payments
  7. QULIPTA $154 14 payments
  8. OLUMIANT $151 12 payments
  9. AJOVY $143 5 payments
  10. SAPHNELO $142 3 payments
  11. Other $860 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

145 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Registered Nurse, General Practice in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record